title: A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.
abstract: OBJECTIVE
  BMS-182751 (JM-216) is an orally bioavailable platinum compound with activity in platinum-sensitive and platinum-resistant preclinical models. The objective was to determine its activity in recurrent/metastatic squamous cell carcinoma of the cervix.
  
  
  METHODS
  We conducted a phase II study of BMS-182751 given at a dose of 30 mg/m(2) daily for 14 days every 5 weeks.
  
  
  RESULTS
  Eighteen patients (pts) with advanced/recurrent squamous cancer of the cervix not amenable to curative therapy with measurable disease who had received no prior chemotherapy for systemic disease were entered, all of whom are evaluable for response and toxicity. Median age was 47 years (35-74 years); all pts had received prior pelvic irradiation (RT); 4 pts had received cisplatin as adjustment therapy with radiation; PS was 0 (6 pts), 1 (7 pts), and 2 (5 pts); sites of disease included nodes (10 pts), pelvis (5 pts), lung (4 pts), and bone (3 pts). Median number of cycles was two (1-6) with 8 pts receiving three or more cycles. Toxicity was modest and usually grade 1 or 2 in severity with the most frequent drug related toxicity being nausea (56%), fatigue (50%), anorexia (39%), diarrhea (39%), vomiting (39%), constipation (28%), and altered taste (22%). Six pts had grade 3 or 4 granulocytopenia and only 1 pt, grade 3 or 4 thrombocytopenia. Two pts had grade 2 or 3 creatinine increases. There were no treatment-related deaths. One pt with a treatment-free interval of 30 years achieved a partial response, while 12 pts had a best response of stable disease.
  
  
  CONCLUSIONS
  BMS-182751 is generally well tolerated, but has limited activity in pts with recurrent cervical cancer.
authors.affiliation: National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada. marc.trudeau@muhc.mcgill.ca
authors.forename: Marc
authors.initials: M
authors.lastname: Trudeau
authors.forename: Gavin
authors.initials: G
authors.lastname: Stuart
authors.forename: Hal
authors.initials: H
authors.lastname: Hirte
authors.forename: Pierre
authors.initials: P
authors.lastname: Drouin
authors.forename: Marie
authors.initials: M
authors.lastname: Plante
authors.forename: Paul
authors.initials: P
authors.lastname: Bessette
authors.forename: Helene
authors.initials: H
authors.lastname: Dulude
authors.forename: David
authors.initials: D
authors.lastname: Lebwohl
authors.forename: Bryn
authors.initials: B
authors.lastname: Fisher
authors.forename: Lesley
authors.initials: L
authors.lastname: Seymour
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D009944:Organoplatinum Compounds; C081294:satraplatin